Hemlibra is a medicine used to prevent or reduce bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII). The medicine is used in: - patients who have developed factor VIII inhibitors, which are antibodies in the blood that act against factor VIII medicines and prevent them from working properly; - patients without factor VIII inhibitors if their haemophilia A is severe or moderate (with severe bleeding phenotype). Hemlibra contains the active substance emicizumab.
Therapeutic Indication
### Therapeutic indication Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency): - with factor VIII inhibitors - without factor VIII inhibitors who have: - severe disease (FVIII < 1%) - moderate disease (FVIII ? 1% and ? 5%) with severe bleeding phenotype. Hemlibra can be used in all age groups.
Therapeutic Area (MeSH)
ATC Code
B02BX06
ATC Item
emicizumab
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
EMA Name
Hemlibra
Medicine Name
Hemlibra
Aliases
N/ANo risk management plan link.
